Genotype-Phenotype Associations in Sotos Syndrome: An Analysis of 266 Individuals with NSD1 Aberrations  by Tatton-Brown, Katrina et al.
Am. J. Hum. Genet. 77:193–204, 2005
193
Genotype-Phenotype Associations in Sotos Syndrome: An Analysis of 266
Individuals with NSD1 Aberrations
Katrina Tatton-Brown,1 Jenny Douglas,1 Kim Coleman,1 Genevie`ve Baujat,2
Trevor R. P. Cole,3 Soma Das,4 Denise Horn,5 Helen E. Hughes,6 I. Karen Temple,7
Francesca Faravelli,8 Darrel Waggoner,4 Seval Tu¨rkmen,5 Vale´rie Cormier-Daire,2
Alexandre Irrthum,1 and Nazneen Rahman,1 for the Childhood Overgrowth Collaboration*
1Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; 2Department of Medical Genetics, Hopital Necker Enfants
Malades, Paris; 3Clinical Genetics Unit, Birmingham Women’s Hospital, Birmingham, United Kingdom; 4Department of Human Genetics,
University of Chicago, Chicago; 5Institut fu¨r Medizinische Genetik, Humboldt-Universita¨t, Charite´, Berlin; 6Institute of Medical Genetics,
University Hospital of Wales, Cardiff; 7Department of Human Genetics, Southampton University Hospital, Southampton, United Kingdom;
and 8Laboratorio di Genetica Umana, Ospedali Galliera de Genova, Genova, Italy
We identified 266 individuals with intragenic NSD1 mutations or 5q35 microdeletions encompassing NSD1 (referred
to as “NSD1-positive individuals”), through analyses of 530 subjects with diverse phenotypes. Truncating NSD1
mutations occurred throughout the gene, but pathogenic missense mutations occurred only in functional domains
( ). Sotos syndrome was clinically diagnosed in 99% of NSD1-positive individuals, independent of516P ! 2# 10
the molecular analyses, indicating that NSD1 aberrations are essentially specific to this condition. Furthermore,
our data suggest that 93% of patients who have been clinically diagnosed with Sotos syndrome have identifiable
NSD1 abnormalities, of which 83% are intragenic mutations and 10% are 5q35 microdeletions. We reviewed the
clinical phenotypes of 239 NSD1-positive individuals. Facial dysmorphism, learning disability, and childhood over-
growth were present in 90% of the individuals. However, both the height and head circumference of 10% of the
individuals were within the normal range, indicating that overgrowth is not obligatory for the diagnosis of Sotos
syndrome. A broad spectrum of associated clinical features was also present, the occurrence of which was largely
independent of genotype, since individuals with identical mutations had different phenotypes. We compared the
phenotypes of patients with intragenic NSD1 mutations with those of patients with 5q35 microdeletions. Patients
with microdeletions had less-prominent overgrowth ( ) and more-severe learning disability (Pp .0003 Pp 3#
) than patients with mutations. However, all features present in patients with microdeletions were also observed5910
in patients with mutations, and there was no correlation between deletion size and the clinical phenotype, suggesting
that the deletion of additional genes in patients with 5q35 microdeletions has little specific effect on phenotype.
We identified only 13 familial cases. The reasons for the low vertical transmission rate are unclear, although familial
cases were more likely than nonfamilial cases ( ) to carry missense mutations, suggesting that the underlyingPp .005
NSD1 mutational mechanism in Sotos syndrome may influence reproductive fitness.
Introduction
The nuclear receptor SET domain–containing protein 1
(NSD1) gene encodes a histone methyltransferase and
is located at chromosome 5q35. NSD1 was initially iso-
lated in a search for proteins that interact with the li-
gand-binding domain of retinoic acid receptor a and sub-
sequently was shown to be the fusion partner of NUP98
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in some cases of childhood acute myeloid leukemia
(Huang et al. 1998; Jaju et al. 2001). NSD1 contains
multiple functional domains, including SU(VAR)3–
9,E(Z),trithorax (SET) and SET-associated (SAC) do-
mains that together mediate the histone methyltransfer-
ase activity of NSD1; a C5HCH and five plant homeo-
domains (PHDs), which are implicated in chromatin regu-
lation and are zinc finger–like motifs characterized by
cysteine and histidine residues; and two proline-tryp-
tophan-tryptophan-proline (PWWP) domains that may
mediate protein-protein interactions and that are often
found in proteins that act at the chromatin level (Aasland
et al. 1995; Stec et al. 2000; Rayasam et al. 2003). NSD1
also contains two nuclear-receptor interaction domains,
NIDL and NIDL, which are typical of those found in
nuclear-receptor corepressors and coactivators, respec-
tively (Huang et al. 1998).
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The functions of NSD1 are not known, but it has
been shown to methylate both H4 K20 and H3 K36,
modifications that are individually associated with tran-
scriptional repression (Rayasam et al. 2003). The pres-
ence of two distinct nuclear-receptor interaction domains
(NIDs) has given rise to the hypothesis that differential
ligand binding to NIDL and NIDL allows NSD1 to both
negatively and positively regulate transcription (Huang
et al. 1998).
In 2002, NSD1 haploinsufficiency was reported in
patients with Sotos syndrome (MIM 117550), a condi-
tion characterized by facial dysmorphism, learning dis-
ability, and childhood overgrowth (Kurotaki et al. 2002).
Subsequently, 1100 individuals with NSD1 abnormal-
ities were reported in the literature (Douglas et al. 2003;
Kurotaki et al. 2003; Rio et al. 2003; Tu¨rkmen et al.
2003; de Boer et al. 2004; Cecconi et al. 2005). The
range and relative contributions of NSD1 abnormalities
and the spectrum of clinical phenotypes associated with
NSD1 have been unclear. In particular, the prevalence
of 5q35 microdeletions in Japanese and non-Japanese
individuals has been controversial. In Japan, 5q35 mi-
crodeletions are the most common cause of Sotos syn-
drome and are predominantly mediated by nonallelic
homologous recombination between flanking low-copy
repeats (Visser et al. 2005). Outside Japan, 5q35 micro-
deletions are uncommon, accounting for only 10% of
affected individuals, and multiple mechanisms are im-
plicated in their generation (Tatton-Brown et al. 2005).
It was postulated that this difference in microdeletion
frequency was due to variation in patient-selection cri-
teria for NSD1 analyses (Kurotaki et al. 2003). How-
ever, it seems more likely that differences in sequence
architecture are responsible, since an inversion poly-
morphism that predisposes to microdeletions appears
to be common in Japan (Tatton-Brown et al. 2005; Vis-
ser et al. 2005).
The range of clinical features associated with Sotos
syndrome is broad, and it has been suggested that this
variability is related to the underlying mutational mech-
anism. Specifically, it was proposed that the phenotypes
of individuals with NSD1 mutations and of those with
5q35 microdeletions differ because some features of So-
tos syndrome, such as overgrowth and learning disability,
are attributable to NSD1, whereas other features, such
as cardiac and renal anomalies, occur only in individuals
with microdeletions and are due to deletion of other
genes (Nagai et al. 2003; Niikawa 2004). It has also been
suggested that NSD1 mutations can cause other over-
growth conditions such as Weaver syndrome (MIM
277590) and Beckwith-Wiedemann syndrome (BWS
[MIM 130650]) (Douglas et al. 2003; Rio et al. 2003;
Baujat et al. 2004).
In the present study, we screened a large series of
subjects with diverse phenotypes for mutations and de-
letions of NSD1, to clarify the range and contribution
of different NSD1 abnormalities and the spectrum of
associated clinical features. We compared the clinical
features of individuals with mutations and microdele-
tions, as well as the clinical features of individuals with
different-sized microdeletions, to investigate whether the
deletion of other genes contributes to the phenotype of
patients with 5q35 microdeletions. Additionally, we in-
vestigated the heritability and phenotypic variability of
NSD1 abnormalities, to provide information for coun-
seling on recurrence and offspring risks and to evaluate
whether prognostic information can be provided by
identification of the underlying mutational mechanism
in individuals with NSD1 abnormalities.
Subjects and Methods
Patients
The research was approved by the London Multicentre
Research Ethics Committee, and consent was obtained
from participating subjects and/or their parents. Through
analyses of 530 individuals, 266 patients with NSD1
aberrations (referred to as “NSD1-positive individuals”)
were identified. This included 179 NSD1-positive indi-
viduals identified through analyses of 443 subjects in the
Childhood Overgrowth Study. Patients recruited into
this study have a broad range of phenotypes, including
a clinical diagnosis of Sotos syndrome, overgrowth and/
or macrocephaly (but without the typical facial features
of Sotos syndrome), and facial features similar to Sotos
syndrome (but no overgrowth). Of 179 subjects, 132
NSD1-positive individuals ascertained through these an-
alyses were from the United Kingdom, and the remainder
had diverse origins. NSD1 analyses of 73 of these in-
dividuals have been published elsewhere (Douglas et al.
2003, in press; Tatton-Brown et al. 2005). The remain-
ing 87 NSD1-positive individuals were identified in col-
laborating centers in France, Germany, Italy, and the
United States, and descriptions of 54 have been pub-
lished elsewhere (Rio et al. 2003; Tu¨rkmen et al. 2003;
Cecconi et al. 2005; Waggoner et al., in press). A stan-
dard clinical questionnaire was requested from all NSD1-
positive individuals and was obtained from 239 of the
individuals. Facial photographs of 290 of the 530 pa-
tients were evaluated independently by three clinical ge-
neticists (T.R.P.C., H.E.H., and I.K.T.), who were un-
aware of the NSD1 status, as described elsewhere (Doug-
las et al. 2003). The patients were categorized into four
phenotypic groups: (1) “typical Sotos syndrome,” (2)
“possible Sotos syndrome,” (3) “Weaver syndrome,”
and (4) “definitely not Sotos or Weaver syndrome.” If
another diagnosis, such as BWS, was thought possible,
this was noted.
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Table 1
Summary of the Number of Patients
with Different NSD1 Abnormalities
Category and Type
of NSD1 Aberration No. of Patients
Intragenic mutations: 233
Frameshift 91
Nonsense 59
Missense 64
Splice site 11
Partial-gene deletions 8
5q35 microdeletions 33
Total 266
Table 2
Intragenic Mutations and Exonic Polymorphisms
in NSD1
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
NSD1 Analyses
The 443 subjects collected through the Childhood
Overgrowth Study were screened for intragenic muta-
tions by use of conformational sensitive gel electropho-
resis and sequencing, as described elsewhere (Douglas et
al. 2003). To identify 5q35 microdeletions, all subjects
were initially analyzed at the highly polymorphic intra-
genic microsatellite marker SOT3 (Douglas et al. 2003).
Individuals who were homozygous at SOT3 were further
analyzed by multiplex ligation-dependent probe ampli-
fication (MLPA) with the use of the SALSA P026B NSD1
kit to identify 5q35 microdeletions, which were confirmed
by quantitative fluorescent PCR and/or microsatellite an-
alyses, as described elsewhere (Douglas et al. 2003; Tat-
ton-Brown et al. 2005). Individuals with the classic facial
features of Sotos syndrome whose mutation screening
was negative were also analyzed by MLPA, even if they
were heterozygous at SOT3, to identify partial-gene de-
letions/duplications. This revealed eight partial-gene de-
letions involving one or more exons (Douglas et al., in
press). NSD1 mutations in patients identified in collab-
orating centers were detected by sequencing and/or de-
naturing high-performance liquid chromatography, and
5q35 microdeletions were identified by FISH, as described
elsewhere (Rio et al. 2003; Tu¨rkmen et al. 2003; Cecconi
et al. 2005; Waggoner et al., in press).
Statistical Analyses
Statistical analyses were performed with the program
R 2.0.1 (R Project for Statistical Computing). The sta-
tistical significance of the clustering of pathogenic mu-
tations in the functional domains of NSD1, comprising
23% of the whole protein, was evaluated with the exact
binomial test. Comparisons of proportions in two-way
contingency tables were performed with the Fisher’s ex-
act test. Height, head circumference, and learning dis-
ability were compared among groups with the Wilcoxon
rank-sum test. The co-occurrence of dichotomous clini-
cal features—cardiac anomalies, renal anomalies, sei-
zures, and scoliosis—was tested with Pearson’s correla-
tion and the Bonferroni correction. All reported P values
are two-sided.
Results
Spectrum of NSD1 Abnormalities
We identified NSD1 abnormalities in 266 of the 530
subjects, of whom 122 were girls and 144 were boys.
The mean parental ages for 46 U.K. NSD1-positive in-
dividuals born between the years 1997 and 2003 were
30.2 years for mothers and 33.2 years for fathers. Na-
tional averages for a comparable time period are 29.1
years for mothers and 32.3 years for fathers.
Of the 266 NSD1-positive individuals, 233 had 180
different intragenic NSD1 mutations, and the remaining
33 individuals had 5q35 microdeletions encompassing
NSD1 (fig. 1A and tables 1 and 2). We identified 117
different truncating NSD1 mutations, including 50 de-
letions of 1–10 bp, 23 insertions of 1–17 bp, 6 in/del
mutations, and 37 nonsense mutations generating stop
codons (table 2). One mutation was an insertion of ∼190
bp from an Alu-Y element into exon 11, which likely
results in premature protein truncation (Douglas et al.,
in press). We detected 10 different mutations affecting
consensus splice-site residues. The precise effect of these
is not known, but they likely result in premature protein
truncation or exon skipping. The truncating and splice-
site mutations were positioned evenly through the gene
(fig. 1B).
To investigate the pathogenicity of missense alterations,
we compared 34 de novo mutations, which we assumed
were disease causing, with 24 sequence variants detected
in unaffected individuals, which we assumed were non-
pathogenic polymorphisms (table 2). The de novo mis-
sense mutations all occurred within functional domains
that comprise 622 of the 2,696 amino acids of the pro-
tein, and this distribution was significantly different from
that expected by chance (exact binomial test, P ! 2#
) (fig. 1B). Furthermore, the pathogenic base sub-1610
stitutions were all nonsynonymous, whereas only 14 of
24 polymorphisms were nonsynonymous (Fisher’s exact
test, ), and none of these was in a func-5Pp 4# 10
tional domain (Fisher’s exact test, ). Eleven12Pp 2# 10
de novo mutations targeted critical cysteine/histidine resi-
dues implicated in chromatin regulation (fig. 1C).
On the basis of these results, we considered 30 other
individuals to have pathogenic missense mutations. These
included 4 individuals with known mutations (i.e., mu-
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Figure 1 Facial features and NSD1 mutations in patients with Sotos syndrome. A, Typical facial features of patients with different NSD1
abnormalities: 5q35 microdeletion, partial NSD1 deletion, truncating mutation, and missense mutation. B, Number of truncating and missense
mutations identified in different NSD1 domains, demonstrating that missense mutations occur only within functional domains. The number of
truncating mutations is at the top of each section of NSD1, and the number of missense mutations is shown at the bottom. Functional domains
are shown as shaded boxes.C, Position of missense mutations (red) in PHD and C5HCH domains, showing bias toward mutations at consensus
cysteine and histidine residues (black).
tations that had occurred de novo in other unrelated
individuals), 10 with mutations that targeted consensus
cysteine/histidine residues in functional domains, and 1
with an in-frame 3-bp deletion within PHD-V; in ad-
dition, six families (15 patients) were identified in which
nonsynonymous mutations of conserved residues in func-
tional domains segregated with Sotos syndrome in the
family. Three mutations (F1177del-2, V1595A, and
Y2058C) that were present in patients with classic Sotos
syndrome were classified as variants of unknown sig-
nificance and were excluded from further analyses. We
strongly suspect that Y2058C, which alters a conserved
residue in the SET domain, and F1177del-2, which re-
sults in the in-frame deletion of two amino acids, are
pathogenic, but we did not have parental DNA to con-
firm that they arose de novo. V1595A is located in a
PHD finger but does not affect a highly conserved resi-
due. Moreover, it was present in both the affected in-
dividual and his unaffected mother and therefore may
not be pathogenic.
We identified eight individuals with distinct exonic
deletions of exons 1 and 2 (four individuals), exons 3–
5, exons 9–13, exons 19–21, and exon 22 (Douglas et
al., in press). Additionally, we identified 33 individuals
with 5q35 microdeletions encompassing NSD1 (Tatton-
Brown et al. 2005). The deletion size in these individuals
was very variable and ranged from 482 kb, in which
only NSD1 was deleted, to 5 Mb, in which at least 54
genes were deleted. In 18 individuals, microdeletions may
have been mediated by nonallelic homologous recom-
bination between flanking low-copy repeats. However,
in 15 individuals, microdeletions cannot be mediated by
recombination between these repetitive elements, and at
least seven different deletion sizes were present among
the 33 individuals (Tatton-Brown et al. 2005).
Familial and Recurrent NSD1 Abnormalities
Thirteen NSD1-positive individuals had affected rela-
tives, and, in 12 families, we were able to demonstrate
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Table 3
Clinical Features of Patients with Recurrent NSD1 Mutations
Mutation
and Patient ID Clinical Feature(s)a
2386-9delGAAA:
COG300 Severe LD, seizures, scoliosis, scaphocephaly
COG514 Moderate LD, seizures, ASD, VSD, PDA
COG523 Moderate LD, scoliosis
3549-50insT:
COG073 Severe LD, seizures, complex cardiac
anomaly, duplex kidney, hypercalcemia
COG095 Moderate LD, seizures, scoliosis
5279-82delTCTG:
COG252 LDb, ASD, scoliosis
COG288 Mild LD, conductive hearing loss
COG455 Mild LD
6596delG:
COG265 Moderate LD, scoliosis, constipation, fixed
flexion deformity of knees
COG272 Mild LD, seizures
R440X:
COG196 No LD, bicuspid aortic valve, left
pyelectasia
COG494 Moderate LD, strabismus, hyperlaxity,
pectus excavatum
R604X:
COG022 Mild LD, seizures, ASD
COG054 Mild LD, cardiac anomaly, scoliosis,
strabismus
COG154 Severe LD, VSD, VUR, GOR,
laryngomalacia
R611X:
COG088 Mild LD, seizures, VSD
COG223 Moderate LD, scoliosis
R1031X:
COG469 Moderate LD
COG502 Mild LD, scoliosis, cataracts, nystagmus
R1072X:
COG133 Severe LD, seizures
COG497 Moderate LD
S1269X:
COG365 Moderate LD, strabismus
COG394 Mild LD
R1322X:
COG538 Mild LD
COG630 Moderate LD
R1811X:
COG103 Mild LD, strabismus
COG251 Moderate LD, seizures
COG321 Mild LD, seizures, ASD, heart conduction
defect, scoliosis
COG465 Moderate LD
COG495 Moderate LD, PUJ obstruction, neonatal
glaucoma
R1984X:
COG190 Mild LD, ASD, hypoplastic thyroid
COG311 Mild LD
COG458 LDb, ASD, VUR
R2005X:
COG323 LDb, sacrococcygeal teratoma
COG482 Moderate LD
R1914C:
COG131 Moderate LD
COG389 Mild LD
(continued)
Table 3 (continued)
Mutation
and Patient ID Clinical Feature(s)a
C1925R:
COG034 Moderate LD, scoliosis
COG144 Mild LD, scoliosis, pectus carinatum,
strabismus
R1952W:
COG371 Mild LD, hemihypertrophy, hepatomegaly
COG434 Severe LD, TGA, scoliosis, cutis laxa
R1984Q:
COG463 Mild LD, seizures, cardiac anomaly, chiari
malformation
COG464 Moderate LD, ASD
COG490 Moderate LD, seizures, scoliosis
COG628 LDb, cryptorchidism, phimosis
Y1997C:
COG233 Moderate LD, scoliosis, pectus excavatum,
hypospadias
COG491 Severe LD
R2017W:
COG308 Mild LD, scoliosis, strabismus
COG500 Moderate LD, scoliosis, VUR
IVS93-6delGAGT:
COG134 Moderate LD, VUR
COG227 Moderate LD, seizures, scoliosis, inguinal
hernia, scaphocephaly
NOTE.—ASD p atrial septal defect; GOR p gastroesophageal re-
flux; PDA p patent ductus arteriosus; PUJ p pelviureteric junction;
TGA p transposition of the great arteries; VSD p ventricular septal
defect; VUR p vesicoureteral reflux.
a In addition to dysmorphism and overgrowth. LD p learning
disability.
b Degree of LD not specified.
that the mutation segregated with the disorder (table 2).
Only one of the families, with affected MZ twin boys,
had a 5q35 microdeletion. Of the 12 families with in-
herited mutations, 7 harbored missense alterations, and
this was significantly greater than the proportion of mis-
sense mutations in nonfamilial cases (48/240; Fisher’s
exact test, ). The mutation was transmittedPp .005
from the mother in nine individuals and from the father
in three individuals. We analyzed 303 unaffected parents
of NSD1-positive individuals, none of whom carried the
mutation/deletion that was present in their children. For
141 nonfamilial cases, samples were available from both
unaffected parents, and analyses confirmed that all cases
had arisen de novo.
Twenty-eight mutations occurred independently in at
least two unrelated individuals and are referred to as
“recurrent” mutations (tables 2 and 3). Twenty-one of
the recurrent mutations were base substitutions, and 18
occurred at CpG dinucleotides.
Clinical Features Associated with NSD1 Abnormalities
Facial dysmorphism, learning disability, and child-
hood overgrowth were each present in at least 90% of
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Table 4
Number of Patients with Height and Head Circumference
within Each Growth Percentile, for Individuals with NSD1
Mutations and 5q35 Microdeletions
GROWTH
PERCENTILE
NO. OF PATIENTS, BY MEASURE AND MUTATION TYPE
Heighta Head Circumferenceb
Intragenic
Mutations
5q35
Microdeletions
Intragenic
Mutations
5q35
Microdeletions
!.4 0 0 0 0
.4 1 1 0 0
2 0 0 1 0
9 0 0 0 0
25 2 0 2 0
50 5 1 6 1
75 6 6 14 0
91 12 4 33 6
98 27 3 31 10
99.6 98 9 105 13
Total 151 24 192 30
a At age 1–10 years.
b At all ages.
NSD1-positive individuals and were designated as car-
dinal features.
Cardinal Features (present in 90% of patients)
Characteristic facial appearance
Learning disability
Overgrowth: height and/or head circumference98th
percentile
Major Features (present in 15% of patients)
Advanced bone age
Cardiac anomalies
Cranial magnetic resonance imaging
or CT abnormalities
Hyperlaxity/pes planus
Maternal pre-eclampsia
Neonatal hypotonia
Neonatal jaundice
Neonatal poor feeding
Renal anomalies
Scoliosis
Seizures
Other Features
Astigmatism
Behavioral problems
Cataract
Cholesteatoma
Conductive hearing loss
Constipation
Contractures
Craniosynostosis
Cryptorchidism
Gastroesophageal reflux
Genu valgum
Hemangioma
Hemihypertrophy
Hydrocele
Hypercalcemia
Hypermetropia
Hyperpigmentation
Hypopigmentation
Hypoplastic nails
Hypospadias
Hypothyroid
Inguinal hernia
Myopia
Neonatal hypoglycemia
Nystagmus
Pectus excavatum
Phimosis
Strabismus
Talipes
2-3 toe syndactyly
Tumors
Umbilical hernia
Vertebral anomalies
The strongest phenotypic feature associated with NSD1
abnormalities was dysmorphism (fig. 1A). All NSD1-
positive individuals were dysmorphic, although this was
often mild. Only 2 of 166 NSD1-positive individuals from
whom photographs were available were phenotypically
scored as “definitely not Sotos or Weaver syndrome,”
both of whom had truncating NSD1 mutations. Even
after reviewing the subjects together with the NSD1 re-
sults, we did not consider the facial features of these two
individuals to be consistent with Sotos syndrome. The
remaining 164 NSD1-positive individuals had been phe-
notypically scored as either “typical Sotos syndrome”
or “possible Sotos syndrome.” Only 2 of 66 individuals
who were phenotypically scored as “definitely not Sotos
or Weaver syndrome” had NSD1 mutations.
Learning disability was very common (present in 97%
of affected individuals). However, the degree of cognitive
impairment was variable, with 21% of affected individ-
uals considered to have “severe” impairment, 46% with
“moderate” impairment, and 30% with “mild” impair-
ment. Only seven individuals had normal intellectual de-
velopment, but there is likely to be a bias toward referral
of children with learning disability and, as a result, NSD1-
positive individuals with normal development may be un-
derrepresented in our analyses. Childhood overgrowth
was also common, with 90% of affected individuals hav-
ing height and/or head circumference at least 2 SDs above
the mean (table 4). For these analyses, we included only
individuals with height measurements taken between the
ages of 1 and 10 years, to limit potential bias resulting
from inaccuracies of measurement in neonates and/or
the effects of puberty. In 60% of affected individuals,
the height and head circumference were both above the
99.6th percentile. However, many individuals had growth
Tatton-Brown et al.: Sotos Syndrome Genotype-Phenotype Analyses 199
Figure 2 Cumulative frequency distribution graphs for patients with NSD1 mutations or 5q35 microdeletions. A, Height distribution. B,
Head circumference distribution. The distributions are significantly different for height (Wilcoxon rank-sum test) but not for head circumference.
parameters within the normal range, and, in four indi-
viduals, the height was below the median (table 4). We
have limited data on adult growth parameters. However,
the height of only 8 of 32 NSD1-positive adult individ-
uals was at or above the 99.6th percentile, and 10 adults
had height at or below the 50th percentile.
Eleven clinical features were present in 15% of af-
fected individuals and were designated major features of
Sotos syndrome (see list above). Advanced bone age was
the most common major feature and was present in 76%
of affected individuals in whom it was measured. How-
ever, bone age was not advanced in nearly one-quarter
of patients, and, therefore, advanced bone age should
not be considered to be an essential feature of Sotos
syndrome. Abnormalities on cranial imaging were also
common, although these were generally nonspecific,
such as dilated ventricles, prominence of the trigone and
occipital horns, and/or hypoplasia of the corpus collosum.
Neonatal problems, such as hypotonia, poor feeding, and
jaundice, were all common (present in ∼70% of patients).
Scoliosis occurred in one-third of patients and was very
variable in severity. Similarly, a broad spectrum of car-
diac anomalies and different seizure types was present
in 21% and 25% of patients, respectively. Maternal pre-
eclampsia was reported in 17% of patients, although it
was not previously known to be associated with Sotos
syndrome. Renal anomalies, particularly vesicoureteral
reflux, were reported for 15% of patients, but this is
likely an underestimate, since relatively few patients had
undergone renal investigations. More information about
the clinical spectrum of associated clinical features of
NSD1-positive individuals with Sotos syndrome is given
in the study by Tatton-Brown and Rahman (2004).
Several other features were reported in at least two
individuals (see list above). Apart from tumors, infor-
mation about these additional features was not specifi-
cally requested on the clinical questionnaire, and their
true frequency in individuals with Sotos syndrome is
therefore uncertain. It is likely that some features, such
as constipation or self-limiting conductive hearing loss
in early childhood, occur in15% of patients and could
be considered major features of Sotos syndrome. We
requested information from all subjects on whether be-
nign or malignant tumors had occurred. Only eight pa-
tients developed tumors, including one neuroblastoma,
three sacrococcygeal teratomas, one presacral ganglio-
neuroma, two acute lymphocytic leukemias, and one
small-cell lung cancer. There were many additional fea-
tures that were reported in only one case, and it is un-
clear whether these were coincidental or related to func-
tional NSD1 abrogation (data not shown).
Genotype-Phenotype Analyses
We compared the clinical features of individuals with
intragenic NSD1 mutations with those of individuals
with 5q35 microdeletions. We compared seven features:
height distribution, head circumference distribution,
learning disability (scored as “none,” “mild,” “moder-
ate,” or “severe”), cardiac anomalies, renal anomalies,
seizures, and scoliosis (all scored as either present or
absent). There were highly significant differences in the
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Figure 3 Bar graph showing the frequency and severity of learn-
ing disability in patients with NSD1 mutations (blackened) and in
those with 5q35 microdeletions (hatched). The actual number of pa-
tients is given above each bar. The distributions are significantly dif-
ferent (Wilcoxon rank-sum test).
height distribution and severity of learning disability.
Patients with NSD1 intragenic mutations were signifi-
cantly taller than patients with 5q35 microdeletions (Wil-
coxon rank-sum test, ) (table 4 and fig. 2A).Pp .0003
By contrast, there was no difference in the head circum-
ference distribution between patients with mutations and
those with deletions (table 4 and fig. 2B). The individuals
with 5q35 microdeletions had more-severe learning dis-
ability (Wilcoxon rank-sum test, (fig. 3),9Pp 3# 10
and there was also a trend toward more cardiac anom-
alies (Fisher’s exact test, ) in individuals withPp .01
microdeletions. However, there was no difference in the
frequency of renal anomalies, scoliosis, or seizures be-
tween individuals with mutations and those with micro-
deletions. There were also no differences in the severity
of learning disability or the frequency of associated fea-
tures in patients with truncating mutations compared
with patients with missense mutations. Pairwise compari-
sons of combinations of major features demonstrated that
the occurrence of cardiac anomalies, renal anomalies, sei-
zures, and scoliosis were all mutually independent.
All of the clinical features shown in the list above were
present in at least two of the patients with mutations,
but some were not seen in the patients with microde-
letions, probably because only 31 individuals with mi-
crodeletions were included in these analyses, compared
with 208 individuals with mutations. Conversely, nephro-
calcinosis was the only feature present in individuals
with microdeletions that was not reported in the indi-
viduals with mutations. Two individuals with 5q35 mi-
crodeletions, with different-sized deletions, had nephro-
calcinosis. However, relatively few patients with muta-
tions had undergone renal investigations, and it is prob-
able that nephrocalcinosis can also occur in patients with
mutations but that it has yet to be reported. The micro-
deletions varied in size from 482 kb to 5 Mb and in-
cluded a minimum of seven different-sized deletions.
There was no correlation between the clinical phenotype
and the size of deletion. Additional details about the
clinical features of the individuals with microdeletions
are given in the study by Tatton-Brown et al. (2005).
We compared the clinical phenotypes of patients with
identical mutations that had arisen independently. This
revealed considerable variability in the degree of learning
disability and associated clinical features in patients with
recurrent mutations (table 3).
Discussion
Multiple Mutational Mechanisms Abrogate NSD1
Function
Multiple mutational mechanisms—including small in-
tragenic insertions and deletions, nonsense mutations,
splicing defects, missense mutations, partial-gene dele-
tions, and whole-gene deletions—can abrogate NSD1
function and can result in human disease. Intragenic trun-
cating mutations occur throughout the gene, and most
are unique. Sequence architecture influences both the
partial- and whole-gene deletions, with several partial-
gene deletions arising through nonallelic homologous
recombination between Alu repeats (Douglas et al., in
press). Similarly, a proportion of whole-gene deletions
are 2-Mb 5q35 microdeletions that are mediated by non-
allelic homologous recombination between low-copy re-
peats flanking NSD1. This recurrent microdeletion is
particularly common in Japan, where a prevalent inver-
sion polymorphism predisposes to the microdeletion
(Tatton-Brown et al. 2005; Visser et al. 2005).
Missense NSD1 mutations are pathogenic only if they
occur within functional domains implicated in chromatin
regulation. Within the PHD, SAC, and C5HCH domains,
mutations predominantly occurred at the consensus cys-
teine and histidine residues that define these domains.
Nineteen of the missense mutations were within the SET
domain and may therefore result in altered methylation
of K20 on H4 and/or K36 on H3. We did not identify
missense mutations in the two NIDs at the 5′ end of the
gene. It is uncertain whether this was because they are
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not pathogenic or because the NIDs together consist of
only 34 amino acids. We did not have sufficient muta-
tions to formally evaluate whether the phenotype dif-
fered in accordance with the domain affected. However,
the phenotypes appeared broadly similar, suggesting that
missense alterations in different domains may have com-
parable effects on NSD1 function. Nonsynonymous base
substitutions in the central portion of NSD1, which is
devoid of recognized functional domains, do not appear
to be deleterious. The function of this part of the gene
is unknown, but it is noteworthy that exon 5, which is
2.56 kb in length, is not present in the NSD1 paralogs,
NSD2, or NSD3, although the functional domains are
all present (Douglas et al. 2005).
NSD1 Abnormalities Are Specific to Sotos Syndrome
We identified 266 individuals with NSD1 abnormali-
ties. Of the 166 individuals for whom we had photo-
graphs, 164 were given a clinical diagnosis of “typical
Sotos syndrome” or “possible Sotos syndrome,” indepen-
dent of the molecular analyses. Conversely, only 2 of 66
individuals given a clinical diagnosis of “definitely not
Sotos or Weaver syndrome” had NSD1 abnormalities.
We analyzed 1500 subjects with a broad range of phe-
notypes, and it is unlikely that there exists a major un-
identified group of cases attributable to NSD1 that was
not included in these analyses. These data therefore in-
dicate that NSD1 abnormalities are essentially specific
to Sotos syndrome.
It has been proposed that NSD1 may cause other over-
growth phenotypes, such as Weaver syndrome and BWS.
In a previous study, we reported three individuals with
atypical Weaver syndrome and with NSD1 mutations and
proposed that NSD1 may cause Weaver syndrome in
some patients (Douglas et al. 2003). In the current anal-
ysis, these three individuals were included in the phe-
notypic review of 290 subjects, but instead of a single
photograph in infancy, multiple pictures at different ages
were available. This resulted in two of the individuals
being classified as having “typical Sotos syndrome” and
one as having “possible Sotos syndrome.” Moreover,
none of the patients with classic Weaver syndrome had
NSD1 mutations. These data suggest there is consider-
able clinical overlap between Sotos and Weaver syn-
dromes, particularly at young ages, but that classic Wea-
ver syndrome is not due to NSD1 abnormalities. We
therefore believe a diagnosis of Weaver syndrome should
be given only if the presence of NSD1 abnormalities has
been excluded. Our practice is to perform NSD1 testing
for all individuals for whom a diagnosis of Weaver syn-
drome is being considered. If this reveals a mutation,
the child is managed as for other NSD1-positive indi-
viduals and a diagnosis of Sotos syndrome is given.
One of the two NSD1-positive individuals whose fa-
cial features were not consistent with Sotos syndrome
was reported elsewhere as having BWS (patient BA [Bau-
jat et al. 2004]). The child is not typical of patients with
BWS since he has learning disability and no macroglos-
sia. The diagnosis of BWS was based on the presence of
neonatal hypoglycemia, umbilical hernia, and persistent
vesicoureteral reflux. However, our data demonstrate
that these features are all associated with Sotos syn-
drome and that vesicoureteral reflux is more commonly
associated with Sotos syndrome than with BWS. Since
overgrowth is a cardinal feature of both conditions, they
will both be included in the differential diagnosis of many
children. Macroglossia is a common feature of BWS that
has never been seen in an NSD1-positive individual,
whereas characteristic facial dysmorphism and learning
disability are almost universal in Sotos syndrome but are
rare in BWS. For most children, these conditions should
therefore be distinguishable by use of clinical criteria.
For rare instances of children with overlapping pheno-
types, investigations of 11p15 and NSD1 may be re-
quired. The clinical management of such children should
be in accordance with the underlying molecular cause.
The Clinical Features of Individuals with 5q35
Microdeletions Are Explicable by NSD1
Haploinsufficiency
It was proposed, on the basis of a comparison of only
5 individuals with mutations and 21 individuals with
microdeletions (Nagai et al. 2003), that the clinical fea-
tures of Sotos syndrome should be classified into two
categories: those caused by NSD1 haploinsufficiency
(overgrowth and learning disability) and those ascribed
to other genes in the deleted interval (such as cardio-
vascular and renal anomalies). Our findings, which are
based on 208 individuals with mutations and 31 indi-
viduals with microdeletions, are not consistent with this
model. The cardinal and major features of Sotos syn-
drome were identified in similar proportions of indi-
viduals with microdeletions and intragenic mutations,
strongly suggesting that these features are due to func-
tional abrogation of NSD1. Overall, individuals with
microdeletions had more-severe learning disability and
less-pronounced overgrowth. Although it is possible that
these differences are attributable to specific genes within
the deleted interval, it is more likely to be a nonspecific
result of the larger chromosomal insult in patients with
microdeletions, since learning disability and growth re-
tardation are very common nonspecific features of mi-
crodeletions throughout the genome (Devriendt and Ver-
meesch 2004). Moreover, despite the large variability in
deletion size (0.4–5 Mb), there was no correlation be-
tween deletion size and clinical phenotype. Indeed, no
additional clinical features were present in the three larg-
est deletions that were not present in at least one of the
three smallest deletions (Tatton-Brown et al. 2005). Over-
all, our data suggest the clinical phenotype of individuals
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with 5q35 microdeletions is primarily attributable to hap-
loinsufficiency of NSD1 and that the deletion of other
genes exerts little phenotypic effect.
The Phenotypic Variability of Sotos Syndrome Is
Largely Independent of Genotype
The phenotype of NSD1-positive individuals was ex-
tremely variable. The three cardinal features—character-
istic facial dysmorphism, learning disability, and child-
hood overgrowth—were present in 90% of affected
individuals, but many other features were also variably
present. The presence of these additional features was
not correlated with and did not appear to be strongly
influenced by the underlying mutational mechanism.
This was most clearly demonstrated by the differing phe-
notypes of individuals with identical mutations. It is cur-
rently unclear what determines the clinical variability of
Sotos syndrome. Stochastic factors, intrauterine environ-
ment, functional polymorphisms in genes that interact
with NSD1, and intrinsic variability in the regulation of
downstream targets of NSD1 may all be implicated.
It is often assumed that Sotos syndrome with severe
learning disability and/or multiple additional features is
due to 5q35 microdeletions (Nagai et al. 2003). Al-
though the phenotypes of individuals with microdele-
tions tend to be at the severe end of the spectrum, Sotos
syndrome in most-severely affected individuals is attrib-
utable to intragenic mutations, which are a much more
common cause of Sotos syndrome, accounting for the
disorder in 180% of patients. Our data also suggest that
missense and truncating NSD1 mutations are similar
with respect to degree of overgrowth, spectrum of learn-
ing disability, and nature and frequency of additional
features.
Sotos Syndrome Is a Fully Penetrant Disorder That Is
Usually Nonfamilial
We screened 1300 parents of NSD1-positive individ-
uals but identified mutations in only 11, all of whom
were clinically diagnosed with familial Sotos syndrome
before the molecular analyses. Thus, we have not seen a
case of nonpenetrance for a confirmed pathogenic NSD1
mutation. Neither have we seen a family with affected
siblings of unaffected parents that would suggest ger-
minal mosaicism. These data indicate that the recurrence
risk for unaffected parents of a child with Sotos syn-
drome is extremely low and that such cases are almost
always the result of de novo mutations. Familial cases
had a markedly increased proportion of missense mu-
tations, compared with nonfamilial cases, and it is in-
teresting that all familial missense mutations occurred
outside the SET domain. This suggests that certain types
of mutations may be more likely to be heritable. How-
ever, affected families with truncating mutations were
also identified.
The reasons for the low vertical transmission rate are
currently unclear. One-third of patients with Sotos syn-
drome have only mild learning disability, and many of
these patients are likely to consider having children in
the future. Our very small series of adult patients with
Sotos syndrome who have been trying to have children
has not revealed any obvious problems during puberty,
conception, pregnancy, or childbirth. Moreover, the out-
comes have been consistent with the expected 50% off-
spring risk of an autosomal dominant disorder. Long-
term prospective follow-up of patients with Sotos syn-
drome will likely be required to clarify these apparently
paradoxical observations.
To date, we have undertaken all NSD1 testing in the
United Kingdom. This includes 124 U.K. subjects who
were clinically judged to have Sotos syndrome by three
clinical geneticists who were unaware of the molecular
results. Of these 124 individuals, 96 have intragenic
NSD1 mutations, 12 have 5q35 microdeletions, 7 have
partial-gene deletions, and 9 have no identified cause.
These data suggest that, in at least 93% of patients,
Sotos syndrome is attributable to NSD1—with 77% of
patients having small intragenic mutations, 6% with
partial-gene deletions, and 10% with whole-gene dele-
tions. Only 7% of patients did not have an identifiable
abnormality in NSD1. Such patients are clinically very
similar to NSD1-positive patients with Sotos syndrome,
and we suspect they also have abrogated NSD1 function.
It is likely such patients harbor either mutations that
were not detected by our heteroduplex analyses or ab-
errations that were not identifiable by our screening
methods, such as regulatory abnormalities. Although we
cannot exclude genetic heterogeneity as the cause of So-
tos syndrome in a small proportion of patients, our an-
alyses demonstrate that Sotos syndrome is attributable
to NSD1 in the great majority of affected individuals.
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